Antimicrobial peptides: agents of border protection for companion animals. by Leonard, Brian C et al.
UC Davis
UC Davis Previously Published Works
Title
Antimicrobial peptides: agents of border protection for companion animals.
Permalink
https://escholarship.org/uc/item/8978458f
Journal
Veterinary dermatology, 23(3)
ISSN
0959-4493
Authors
Leonard, Brian C
Affolter, Verena K
Bevins, Charles L
Publication Date
2012-06-01
DOI
10.1111/j.1365-3164.2012.01037.x
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Antimicrobial peptides: agents of border protection for
companion animals
Brian C. Leonard*, Verena K. Affolter† and Charles L. Bevins*
*Department of Microbiology and Immunology, UC Davis School of Medicine, Davis, CA 95616, USA
†Department of Veterinary Pathology, Microbiology and Immunology, UC Davis School of Veterinary Medicine, Davis, CA 95616, USA
Correspondence: Charles L. Bevins, Department of Microbiology and Immunology, UC Davis School of Medicine, Davis, CA 95616, USA.
E-mail: clbevins@ucdavis.edu
Over the past 20 years, there have been significant inroads into understanding the roles of antimicrobial peptides
in homeostatic functions and their involvement in disease pathogenesis. In addition to direct antimicrobial activ-
ity, these peptides participate in many cellular functions, including chemotaxis, wound healing and even determi-
nation of canine coat colour. Various biological and genetic approaches have helped to elucidate the role of
antimicrobial peptides with respect to innate immunity and host defense.
Associations of antimicrobial peptides with various skin diseases, including psoriasis, rosacea and atopic dermati-
tis, have been documented in humans. In the longer term, therapeutic modulation of antimicrobial peptide
expression may provide effective new treatments for disease.
This review highlights current knowledge about antimicrobial peptides of the skin and circulating leukocytes, with
particular focus on relevance to physiology and disease in companion animals.
Introduction
Antimicrobial peptides (AMPs) are naturally occurring
antimicrobials found throughout nature. In mammals,
AMPs are expressed by both epithelial cells and phago-
cytic leukocytes, and they possess broad-spectrum anti-
microbial activity against bacteria, fungi and viruses.1 In
addition, AMPs can promote chemotaxis, wound healing
and, interestingly, determination of coat colour in dogs
(Figure 1).2–4 Antimicrobial peptides have been identified
and described in all mammals studied,5 including com-
panion animals.4,6,7 The two major subfamilies of AMPs
in mammals are cathelicidins and defensins,1 which
exhibit similar physical properties and many overlapping
activities (Figure 2).
Mammalian skin is generally thought of as a thin lining
that separates the host from the external world. Despite
constant confrontation with pathogens, the incidence of
skin infections remains relatively low. The epidermis pro-
vides a physical barrier to microbial invasion and prevents
favourable niches for pathogens. In the event that this
physical barrier is breached, a co-ordinated innate
immune response, involving macrophages and neutroph-
ils, is activated to eliminate the invaders.8 However, this
view of innate immunity is incomplete. Recent evidence
shows that the epidermis is much more than just a physi-
cal barrier.8 Indeed, epidermal keratinocytes are equipped
with pathogen recognition receptors and can detect and
respond to potential invaders.8 This response helps to
initiate a co-ordinated inflammatory response, which
includes recruitment of leukocytes. Another important
element of this defensive response is the induction of
AMPs by keratinocytes.5 This review highlights the
current knowledge of AMPs in dogs, cats and humans,
with particular relevance to skin biology and disease.
Repertoire of AMPs
Defensins
Defensins are small, cationic peptides that are expressed
by certain phagocytic leukocytes and epithelial cells.
These peptides possess broad-spectrum antimicrobial
activity (Figure 2).5 The defensins are categorized into
three subfamilies, a, b and h, based on their disulfide
bonding array and primary amino acid sequence.5 Evolu-
tionarily speaking, the b-defensins are the oldest of the
defensins, tracing their ancestry back to the horseshoe
crabs.9 The host genomic repertoire of defensins varies
greatly between species, in both number of defensins
encoded and sequence diversity.10 The a-defensins have
been found in primates, glires and horses, but not
in dogs,10,11 whereas the b-defensins have been docu-
mented in all mammals and some lower order species as
well.5 The h-defensins are unique in that they are
encoded in the genomes of humans and nonhuman
primates, although a functional gene product has only
been found in nonhuman primates.12
A comparative genome analysis of the dog has identi-
fied 43 b-defensin genes and pseudogenes. Much of the
gene nomenclature has been modelled after putative
human orthologues.10 Canine b-defensins are arranged in
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four gene clusters that correspond to those in rats, mice
and humans.10 The best-characterized b-defensin cluster
in humans is encoded on chromosome 8p23.1, which
is syntenic with the b-defensin cluster on chromo-
some 16 of dogs (Figure 3).10 The first canine defensin
gene identified was named canine b-defensin-1 (CBD1),
and appears to encode the orthologue of BD1 in rodents
and humans. The remaining canine defensin genes are
numbered CBD102–CBD142 (to correspond roughly to
their human counterparts); two additional defensin genes
are referred to as canine sperm-associated antigen
(SPAG)11c and SPAG11e.10 The study by Patil et al.10
clearly defines and names all of the defensins in the
canine genome. Owing to the already complex nomencla-
ture in the defensin field, we encourage fellow investiga-
tors to adopt this scheme as a consistent method of
labelling canine defensins to reduce ambiguity and ease
the interpretation of data between studies.
Cathelicidins
Cathelicidins are AMPs that also possess broad-spectrum
activity, yet they exhibit great diversity in both sequence
and structure (Figure 2).13 Like defensins, the cathelicidin
precursor has three domains: a signal sequence, a
propeptide domain and a mature peptide at the
C-terminus.14 However, the unifying feature of cathelici-
dins is not the sequence of the mature peptide, but the
propeptide domain, a region with sequence similarity to
the protease inhibitor, cathelin.13 The sequence of this
propeptide domain is highly conserved across diverse
species.14,15 In contrast, the mature peptide sequence
varies widely between species and can be classified into
the following four subfamilies: linear a-helical; proline-
and arginine-rich; tryptophan-rich; or disulphide bond-
containing peptides.14 In addition to sequence diversity
of the mature peptide, there is considerable variability in
the number of cathelicidins encoded by genomes of
various species.15 Humans (LL-37), mice (CRAMP), dogs
(K9CATH) and cats (feCath) express a single cathelicidin,
Figure 1. Antimicrobial peptides serve as peptide effectors of innate
immunity, and they participate in the co-ordination of inflammatory
responses. Abbreviations: LPS, lipopolysaccharide; and PAMP, path-
ogen-associated molecular patterns.
Figure 2. Venn diagram showing the similarities and differences between the two major subgroups of antimicrobial peptides, cathelicidins and
defensins. Overlap indicates similar peptide characteristics, whereas the nonoverlapping regions are specific differences between the subgroups.
Abbreviations: LPS, lipopolysaccharide; and TLR9, Toll-like receptor 9.
ª 2012 The Authors. Veterinary Dermatology
178 ª 2012 ESVD and ACVD, Veterinary Dermatology, 23, 177–e36.
Leonard et al.
whereas horses, pigs, cows and goats express multiple
cathelicidins.7,15,16
Expression patterns of AMPs
Depending on the particular peptide in question, the
expression of AMPs is either constitutive or inducible by
various stimuli, including inflammation and the presence
of pathogens.5,17
Defensins
The b-defensins expressed in human skin include human
b-defensin 1 (hBD-1),18 hBD-219 and hBD-3.20 Canine
skin highly expresses b-defensins CBD1 and CBD1036,
the putative orthologues of hBD-1 and hBD-3, respec-
tively.10 There is no clear orthologue of hBD-2. Indeed,
due to differences in gene structure and tissue expres-
sion, CBD102 is not similar to hBD-2.10 The CBD102
gene contains three exons,10 and analysis of mRNA from
multiple tissues indicates that CBD102 expression is lim-
ited to the testes (B.C.L. and C.L.B., unpublished data),
whereas the gene encoding hBD-2 (named DEFB4) has
two exons and is broadly expressed in many tissues,
including human skin and colon.19,21 Expression of feline
b-defensins has not been reported to date; however,
feline b-defensin 103 (feBD103) expression has been
identified in cat skin (B.C.L. and C.L.B., unpublished
data).
Initially, hBD-1 was identified in haemofiltrate from dial-
ysis patients and subsequently localized to epithelial cells
from many tissues, including pancreas, kidney and
skin.18,22,23 Expression of hBD-1 is constitutive. The pro-
moter region of hBD-1 lacks transcription factor binding
sites often involved in inflammation, such as nuclear
factor-jB or AP-1 (activator protein-1),24 and the hBD-1
transcript is not upregulated during inflammation.21 In
contrast, baseline expression of hBD-2 is low in human
keratinocytes, but can be upregulated with inflammation
or pathogenic stimulation.19,25,26 Analysis of the promoter
region of hBD-2 has revealed two functional nuclear fac-
tor-jB binding sites that are responsible, in part, for its
upregulation.27 Another b-defensin that exhibits inducible
expression in human skin is hBD-3, the orthologue of
CBD-103 in dogs. Expression of hBD-3 can be induced by
tumour necrosis factor-a or contact with bacteria, and in
wound-healing responses.26,28
Studies have begun to explore b-defensin expression
and function in dogs. Expression has been identified in
the testes,29 kidney, palatine tonsil, trachea, lung, gastro-
intestinal tract, liver, spleen, peripheral blood mono-
nuclear cells, bone marrow and skin (Figure 4).4,6,30–32 To
evaluate possible induced b-defensin expression, canine
primary tracheal epithelial cells were treated with both
lipopolysaccharide and canine respiratory coronavirus;
however, neither stimulus was sufficient to upregulate
CBD103 expression.32 Further studies are needed in
order to understand patterns and regulation of canine de-
fensin expression more fully.
Cathelicidins
Human cathelicidin, LL-37, exhibits constitutive and
inducible expression in many different cell types. High
levels of LL-37 are found in the bone marrow, and the
peptide localizes to specific granules in the neutrophil.33
Although constitutive LL-37 expression is very low in
Figure 3. Defensin gene cluster on canine chromosome 16. Canine
chromosome 16 encodes a cluster of b-defensin genes. The genetic
organization of this cluster is very similar to the orthologous defensin
cluster on human chromosome 8p. Within the defensin cluster,
some b-defensin genes exhibit gene copy-number polymorphism,
beginning with CBD102 (indicated by a continuous line). The distal
end of the cluster has yet to be defined (indicated by a dotted line).
Figure adapted from Patil et al.10
Figure 4. Differential expression of defensins. Defensins are
expressed in epithelial cells in many different organs, including the
mouth, skin, reproductive tract, gastrointestinal tract and lungs. In
the dog, a variant of CBD103 is involved with the determination of
coat colour.
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keratinocytes, treatment with 1,25-(OH)2 vitamin D3
induced LL-37 mRNA expression 100-fold over
baseline.34 Vitamin D3 also induces LL-37 expression in
monocytes and macrophages, and can lead to enhanced
intracellular killing35 and promote autophagy in the
co-ordinated killing of Mycobacterium tuberculosis.36 This
responsiveness to vitamin D3 involves the vitamin D3
responsive element (VDRE) in the 5¢ promoter region of
the human cathelicidin gene.37 When comparing cathelici-
din genes across species, the VDRE is conserved among
primates, but is not present in other species, including
mice, dogs and cats.7,37
Canine cathelicidin, K9CATH, is expressed in epithelial
cells and leukocytes.16,31 High expression is seen in bone
marrow, and lower levels are present in the gastrointesti-
nal tract, liver, spleen, testes16 and skin.31 The 5¢ pro-
moter region of K9CATH does not contain any VDRE
sequences, suggesting that this gene will not respond to
vitamin D3.
37 This suggests that topical vitamin D3 appli-
cation to canine skin may not be clinically effective in
increasing cathelicidin expression. Similar to its canine
orthologue, feline cathelicidin, feCATH, is highly expressed
in the bone marrow.7 The peptide immunolocalizes to
neutrophils, with lower levels of expression detected in the
skin.7 As in the canine gene, a VDRE sequence was not
observed in the 5¢promoter region of the gene.7
Activity of AMPs
Antimicrobial activity
Cationic AMPs are generally thought to exert their anti-
microbial effect through permeabilization of target micro-
bial membranes. The positively charged arginine and
lysine residues of AMPs interact favourably with the
negatively charged microbial membranes via electrostatic
interaction.38 This interaction has been demonstrated
both with artificial vesicles composed of anionic lipids and
with bacteria, such as Escherichia coli.39,40 Following
charge-mediated interaction of AMPs and the membrane,
the amphipathic nature of the peptide promotes hydro-
phobic integration into the membrane.39 The result is
initially formation of pores, which can dissipate electro-
chemical gradients, and at high concentrations of AMP,
severe membrane disruption and a release of intracellular
contents (Figure 5).39
Interestingly, recent data have provided evidence for a
specific intracellular target for some defensins against
Gram-positive bacteria.41–44 Wei et al. synthesized sev-
eral defensins using D-amino acids, rather than the natural
L-isomers. Each defensin peptide retained equal activity
against Gram-negative bacteria, presumably because the
mechanism described above involving pore formation
is independent of stereochemistry.41 In contrast, the
D-enantiomers lost antimicrobial activity against Staphylo-
coccus aureus, indicating the importance of peptide
chirality for activity against Gram-positive bacteria. Sub-
sequent studies demonstrate that Lipid II, an essential
component for bacterial cell wall biosynthesis, is the
target for (at least) some defensins against Gram-positive
bacteria (Figure 5).42–44 These insights into specific
mechanisms of antimicrobial killing may help propel
development of novel therapeutics.
Recent studies have focused on the antimicrobial activ-
ity of canine AMPs and pathogens that frequently compli-
cate chronic skin disease in dogs. Canine cathelicidin
displayed potent, broad-spectrum antimicrobial activity
against various pathogens, including S. aureus, E. coli
and Listeria monocytogenes.16 In addition, Fazakerley
et al.45 demonstrated equal antimicrobial activity of syn-
thetic hBD-3 against Staphylococcus pseudintermedius
isolated from both healthy canine skin and dogs with ato-
pic dermatitis.
Bacterial resistance
In retaliation to the antimicrobial defenses elaborated by a
given host, pathogens have developed methods of resis-
tance. Proteolytic degradation of AMPs is one mecha-
nism by which bacteria evade innate immune measures.5
The human cathelicidin, LL-37, can be proteolytically
degraded by bacterial proteases, including SpeB of Strep-
tococcus pyogenes and elastase B of Pseudomonas
aeruginosa.46,47 Staphylococcus aureus expresses a
metalloproteinase, aureolysin, which can also degrade
LL-37.48 The intramolecular disulfide bonds of defensins
help protect this class of AMP from proteolysis.49
In addition to degradation, some pathogens express
proteins that can directly bind and neutralize AMPs. Lyso-
genic strains of S. aureus produce staphylokinase, which
binds defensins and inhibits their ability to kill.50 Likewise,
streptococci produce a protein called streptococcal
inhibitor of complement that can neutralize defensins.51
Many bacteria have the ability to modulate the overall
charge of their membranes, making them less anionic,
and hence resistant to cationic AMPs. These enzyme-
mediated modifications of lipopolysaccharide were first
described in the Gram-negative pathogen Salmonella
Typhimurium.52 The external bacterial membranes of the
Gram-positive bacteria S. aureus and streptococci contain
negatively charged teichoic acids. However, through the
addition of positively charged D-alanine esters to teichoic
acids, S. aureus and streptococci can repel the electro-
static attraction of cationic peptides, protecting the bacte-
ria from AMPs.53,54 Staphylococcus aureus can modify
the anionic phosphatidylglycerol on the bacterial mem-
brane through the addition of cationic L-lysine.55,56 These
examples of bacterial countermeasures represent ongo-
ing coevolution of host–pathogen interactions. Insights
into the molecular mechanisms of resistance to AMPs
may aid in development of future therapeutics.
Chemotaxis
Investigations into the chemotactic activity of defensins
and cathelicidins for leukocytes have helped to establish
a link between AMPs and the adaptive immune system.
Leukocytes are attracted by and migrate towards a
gradient of AMPs expressed at the site of infection.57 In
humans, neutrophil-derived defensins and LL-37 can
chemoattract monocytes, naı¨ve T cells and immature
dendritic cells.58–60 Human b-defensins, including hBD-2
and hBD-3, expressed at the epithelial surface have the
ability to chemoattract immature dendritic cells and
memory T cells through the chemokine receptor
CCR6.2,61 To gain insight into the structure–function rela-
tionship of these b-defensins, truncation mutants and
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peptides lacking a complete disulfide array were gener-
ated.62 The data support the idea that both the tertiary
structure surrounding the N-terminus and specific resi-
dues at this site mediate the interaction between hBD-3
and CCR6.62,63 This structure–function relationship has
been further substantiated using the mouse orthologue
of hBD-3, Defb14.62–64 Finally, hBD-2 and hBD-3 have
been shown to be chemotactic for monocytes through
CCR2.65 It will be important to evaluate the chemotactic
properties of canine and feline orthologues of the hBD-3,
because it will provide increased knowledge of the inter-
actions between AMPs and adaptive immunity, as well
as providing insight into the structure–function relation-
ships of b-defensins.
Coat colour
Besides serving host defense functions, recent investiga-
tions have implicated defensins in dominant black coat
colour in dogs.4 Coat colour in mammals is primarily
determined by the interaction of the Agouti peptide with
the melanocyte receptor, Mc1r (Figure 6).66–68 Constitu-
tive signalling by Mc1r on the surface of melanocytes
results in the production of eumelanin, or black pig-
ment.69 The Agouti peptide can bind Mc1r and antagonize
Mc1r signalling, resulting in the production of pheomela-
nin, or red ⁄ yellow pigment within melanocytes.68 Differ-
ential signalling and genetic variation in Agouti and Mc1r
account for much of the variation found in mammalian
coat colour.70 In dogs, however, the dominant black coat
colour, seen in breeds such as Labrador retrievers, could
not be explained by simple interactions between Agouti
and the Mc1r receptor.71
In 1957, Little hypothesized that dominant black coat
colour in the domestic dog was due to an unusual allele
of Agouti.71 Subsequent studies of dominant black colour
proved that there is a separate gene, independent of
Agouti, that is responsible for the phenotype, an allele in
the canine genome termed the K locus.72,73 In 2007,
Candille and colleagues4 identified CBD103 as the gene
responsible for the dominant black coat colour using link-
Figure 5. Schematic diagram of antimicrobial killing by antimicrobial peptides. Experimental evidence supports a model of initial electrostatic
attraction of cationic peptides to anionic microbial membranes. Subsequent to binding, amphipathic peptides can insert into membranes to medi-
ate bacterial killing. Recent evidence has shown that certain defensins can kill Gram-positive bacteria through binding Lipid II and preventing
biosynthesis of peptidoglycan. Blue circles with (+) represent cationic peptides, grey circles with ()) represent anionic bacterial membranes, and
yellow circles are intermediates in peptidoglycan biosynthesis. Red X indicates reaction step that is inhibited by cationic peptides binding to
Lipid II. Figure adapted from both Ganz5 and Sass et al.44
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age and association mapping. Specifically, a variant of
CBD103, referred to as CBD103DG23, was found to be
responsible for dominant black coat colour. Compared
with CBD103, CBD103DG23 has a three base-pair dele-
tion, resulting in omission of glycine residue 23 at the
N-terminus of the mature defensin peptide.4 As a result,
the CBD103DG23 variant peptide has the ability to bind to
the Mc1r with high affinity, working as a neutral antago-
nist, thus preventing Agouti from binding and inhibiting
this receptor.4 Binding of CBD103DG23 allows unabated
signalling from Mc1r to synthesize eumelanin, or black
pigment.4 This relationship between defensins and coat
colour was quite unexpected and implies new possibili-
ties for noncanonical functions of defensins, independent
of innate immunity.
Reproduction
Defensins play an important role in sperm maturation,
capacitation and adherence to uterine mucosal epithelial
cells. As sperm migrate through the specialized regions
of the epididymis, their surfaces are modified by the
adsorption of various proteins made by epididymal cells,
including certain b-defensins.74–76 For example, b-defen-
sin 126 (DEFB126) is important for mobility of primate
sperm through cervical mucus and binding to oviductal
epithelial cells, which provides a reservoir of viable sperm
for fertilization.77,78 Manipulations of sperm that resulted
in loss, masking or alteration of DEFB126 resulted in a
reduced ability of the sperm to traverse cervical mucus
and bind oviductal epithelial cells.77,78 A recent study
reported that a genetic variant in DEFB126 is common in
humans and is associated with subfertility.79
Genetic variation of AMPs
Genetic organization: gene copy-number polymorphism
Most mammalian genes are diploid, meaning that one
copy is inherited maternally and another copy is inherited
paternally, yielding a total of two gene copies per gen-
ome. However, recent investigations into genomic struc-
ture have identified many regions of genomic DNA that
are present in multiple copies rather than diploid. Remark-
ably, for some regions the number of copies is variable
from individual to individual.80 This type of genetic vari-
ability exists not only in humans, but also in dogs, and is
referred to as copy-number variation.81 Interestingly, the
human b-defensin cluster on chromosome 8p23.1, includ-
ing the genes that encode hBD-2 and hBD-3, have under-
gone duplication events whereby this cluster repeats
more than once on a given chromosome, allowing for a
total gene copy-number greater than two.82,83 In dogs,
the orthologous gene cluster of b-defensins on chromo-
Figure 6. Coat colour determination in the dog. (a) Constitutive signalling of the Mc1r receptor, localized to the surfaceofmelanocytes, in theabsence
of a ligand, resulting in the production of eumelanin (black pigment). (b) Defective Mc1r signalling results in the synthesis of pheomelanin (yellow or red
pigment). (c) The Agouti peptide antagonizes the Mc1r signalling, resulting in the synthesis of pheomelanin. (d) The variant form of CBD103,
CBD103DG23, serves as a neutral antagonist of Mc1r and allows the melanocyte to synthesize eumelanin. Figure adapted from Candille et al.4 with
input from Gregory S.Barsh.
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some 16, including CBD103, also exhibits gene copy-
number variation (Figure 3),84 although the extent of
variation and breeds that specifically vary in copy number
have yet to be reported. The relationship between gene
copy-number variation and disease is being intensively
studied.83 Disorders associated with b-defensin gene
copy number are discussed in the following section.
Antimicrobial peptides and disease
Psoriasis
Psoriasis is a common chronic inflammatory skin disease
of humans that affects as many as 1–2% of the popula-
tion in the USA. With the exception of a mouse model,
psoriasis has not been recognized in other species, and it
is not a disease of dogs or cats. However, salient features
of this human disease provide an opportunity to illustrate
roles of antimicrobial peptide in chronic inflammatory
disorders. Psoriatic patients have overt skin lesions, but
these lesions are rarely infected,85 and the psoriatic
scales overlying the lesions are especially rich in AMPs.19
High levels of hBD-2, hBD-3 and LL-37 have been
extracted from the psoriatic scales, and epidermal mRNA
expression is significantly higher in lesional skin when
compared with either nonlesional skin or healthy skin
from control subjects.19,25,86 The increased AMP expres-
sion and incorporation into the psoriatic scales is thought
to prevent infection. On the contrary, the increased AMP
expression could also exacerbate disease due to non-
antimicrobial activities of AMPs, such as chemotaxis and
DNA binding.87
In addition to the increased AMP expression in psori-
asis, Hollox et al.88 have identified an association
between psoriatic patients and increased gene copy
number. In two separate population cohorts, individuals
with six or more gene copy numbers in the b-defensin
cluster on chromosome 8 (including hBD-2 and hBD-3)
had an increased risk of developing psoriasis. On the
contrary, individuals with two or three copies of the
b-defensin cluster had a reduced risk of developing
psoriasis.
Atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin
disease due to an allergic response to nonpathogenic
environmental antigens, affecting upwards of 10% of
human and canine populations.89–91 Clinical and histologi-
cal similarities between human and canine AD allow
researchers to make applicable comparisons.92 A similar-
ity amongst human and canine patients with AD is the
presence of a dysfunctional epidermal barrier.92 Second-
ary bacterial infections, S. aureus in humans and Staphy-
lococcus pseudintermedius in dogs, can exploit the
dysfunctional barrier, colonizing and complicating skin
lesions of AD patients.93
Ong et al.86 demonstrated reduced expression of
LL-37 and hBD-2 in AD lesional skin when compared with
healthy and psoriatic skin. To study the mechanism of
reduced AMP expression, the investigators exposed
keratinocytes in culture to the T-helper 2 cytokines
interleukin-4 (IL-4) and interleukin-13 (IL-13), both of
which are known to be overexpressed in AD lesional
skin.86 Treatment of keratinocytes with IL-4 and IL-13
reduced the expression of hBD-2, even when co-
incubated with the proinflammatory cytokine, tumour
necrosis factor-a.86 Another study of AD skin lesions
revealed that hBD-3, known to have anti-staphylococcal
activity, was also reduced in AD lesional skin due to the
presence of IL-4 and IL-13.94 In addition, it has been
observed that AD patients have reduced mobilization of
hBD-3, predisposing them to S. aureus infection.95 How-
ever, a recent study by Harder and colleagues demon-
strates increased AMP expression in patients with AD
when compared with nonlesional skin and control sub-
jects.96 It is possible to conclude that AD patients with
severe disease and a history of recurrent skin infections
are unable to upregulate AMP fully to levels required to
prevent complicating infections.
In canine AD, CBD1 has been shown to have increased
expression in lesional and nonlesional skin when com-
pared with healthy control animals.30 In contrast, lesional
and nonlesional skin exhibited reduced expression of
CBD103.30 This reduction of CBD103 expression may
predispose dogs with AD to developing secondary
S. pseudintermedius infections.
Conclusions
Antimicrobial peptides play an important role in host
immunity, in particular at the skin–environment interface.
Not only do they possess direct antimicrobial activity, but
these peptides also play important roles in shaping host
microbiota, chemotaxis, lectin binding, pathogen-associ-
ated molecular pattern neutralization, reproduction and
coat colour in dogs. There is a great degree of variability
in terms of the families and numbers of AMPs encoded
by the genome of each species. It is likely that the reper-
toire of AMPs elaborated by each species is a reflection
of their environmental niche, mainly the pathogens that
they individually encounter. Importantly, altered expres-
sion of AMPs in certain disease states, such as canine
and human AD, and psoriasis in humans, predisposes the
host to secondary infection or exacerbation of ongoing
inflammation, respectively. Further studies of AMPs in
veterinary species are needed to define the expression of
these peptides, determine genetic variations, evaluate
antimicrobial activities, as well as other functions, and
investigate their role in disease.
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Re´sume´
Au cours de ces 20 dernie`res anne´es, il y a eu d’importantes avance´es de la compre´hension des roˆles des
peptides antimicrobiens dans leurs fonctions home´ostatiques et leur implication dans la pathoge´nie des
maladies. En plus de leur activite´ antimicrobienne directe, ces peptides participent a` de nombreuses fonc-
tions cellulaires, comprenant la chimiotaxie, la cicatrisation et meˆme la de´termination de la couleur de
pelage chez le chien. Des approches biologiques et ge´ne´tiques varie´es ont aide´ a` e´lucider le roˆle des
peptides antimicrobiens au niveau de l’immunite´ inne´e et des de´fenses de l’hoˆte.
Les associations entre les peptides antimicrobiens et diverses dermatoses, incluant le psoriasis, la rosace´e
et la dermatite atopique ont e´te´ documente´es chez l’homme. A plus long terme, la modulation the´rapeu-
tique de l’expression des peptides antimicrobiens pourraient fournir de nouveaux traitements efficaces de
ces maladies.
Cet article passe en revue les connaissances actuelles sur les peptides antimicrobiens de la peau et des
leucocytes circulants. Un accent particulier est donne´ sur la pertinence de la physiologie et des maladies
chez les animaux domestiques.
Resumen
Durante los u´ltimos 20 an˜os ha habido avances significativos para entender el papel de los pe´ptidos antimi-
crobianos en las funciones homeosta´ticas y su implicacio´n en la patogenia de las enfermedades. Adema´s
de tener actividad antimicrobiana directa, estos pe´ptidos participan en muchas funciones celulares, incluy-
endo quimiotaxis, cicatrizacio´n de heridas, e incluso la determinacio´n del color de la capa en perros. Diver-
sas investigaciones biolo´gicas y gene´ticas han ayudado a aclarar el papel de los pe´ptidos antimicrobianos
en la inmunidad innata y en la defensa del hospedador.
En seres humanos se han documentado las asociaciones de pe´ptidos antimicrobianos con varias
enfermedades de la piel, incluyendo psoriasis, rosacea y dermatitis ato´pica. A ma´s largo plazo, la modula-
cio´n terape´utica de la expresio´n de pe´ptidos antimicrobianos puede proporcionar nuevos tratamientos efic-
aces frente a enfermedades.
Esta revisio´n ensalza el conocimiento actual sobre pe´ptidos antimicrobianos de la piel y de los leucocitos
circulantes, con particular e´nfasis en la importancia de la fisiologı´a y el estado de enfermedad en animales
de compan˜ı´a.
Zusammenfassung
Im Verlauf der letzten 20 Jahre hat es signifikante Durchbru¨che bezu¨glich dem Versta¨ndnis der Rolle, die
antimikrobielle Peptide bei der Funktion der Homoo¨stase spielen, sowie ihre Beteiligung bei der Pathoge-
nese von Krankheiten gegeben. Zusa¨tzlich zu ihrer direkten antimikrobiellen Wirkung spielen diese Peptide
eine Rolle bei zahlreichen zellula¨ren Funktionen, wie bei der Chemotaxis, bei der Wundheilung und sogar
bei der Bestimmung der Haarfarbe des Hundefells. Verschiedene biologische und genetische Ansa¨tze
haben dazu beigetragen, die Rolle der antimikrobiellen Peptide im Bezug auf angeborene Immunita¨t und
Abwehrmechanismen des Organismus zu beleuchten.
Die Zusammenha¨nge antimikrobieller Peptide mit zahlreichen Hauterkrankungen, wie Psoriasis, Rosacea
und atopischer Dermatitis sind beim Menschen beschrieben. Auf lange Sicht ko¨nnte eine therapeutische
Modulation der Expression der antimikrobiellen Peptide wirksame neue Behandlungen fu¨r Krankheiten
bereitstellen.
Diese Review befasst sich vor allem mit dem momentanen Wissen u¨ber antimikrobielle Peptide der Haut
und zirkulierender Leukozyten mit speziellem Fokus ihrer Relevanz im Bezug auf Physiologie und Erkrank-
ungen bei Haustieren.
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